Nanoparticle delivery of cancer drugs.

By Andrew Z. Wang, Robert Langer, O. Farokhzad. Annual Review of Medicine, 2012

1,457 citations recorded by the source corpus.

Subfields: Biomaterials, Biomedical Engineering, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/d44e40927ffd5544e6473bbb36044e8428ff0cd4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. A. Anselmo
2. S. Mitragotri
3. O. Mustapha
4. S. Shafique
5. Izhar Ullah
6. O. S. Qureshi
7. F. Din
8. Alam Zeb

In Biomedical Engineering

1. A. Anselmo
2. S. Mitragotri
3. O. Mustapha
4. S. Shafique
5. Izhar Ullah
6. O. S. Qureshi
7. F. Din
8. Alam Zeb

In Molecular Biology

1. O. Mustapha
2. S. Shafique
3. Izhar Ullah
4. O. S. Qureshi
5. F. Din
6. S. Mitragotri
7. A. Anselmo
8. Alam Zeb

Citations in the corpus

• Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors (2017, background): “6 Moreover, it leads to a higher drug concentration inside tumor but reduces drug concentration in normal tissues.”
• Nanoparticles in the clinic (2016, background): “Organic nanoparticles can be designed and formulated to offer enhanced drug protection, controlled release, extended circulation, and improved targeting to diseased tissues as compared to their free drug counterparts.(25,26) Likewise, inorganic nanoparticles benefit from these same advantages, and a”